Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: End Stage Renal Disease

In brief

The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb) levels in chronic hemodialysis subjects who receive SFP via the dialysate versus subjects who receive conventional dialysate without iron.

Key facts

Study ID
NCT01286012
Run by
Rockwell Medical Technologies, Inc.
People needed
108
Starts
2011-01-01
Expected to finish
2013-01-01
Last updated by the study team
2018-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.